CELU: Celularity Inc - Class A Company Profile & Statistics

About

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.

Info & Links

CEO

Robert J. Hariri

Headquarters

170 PARK AVE
FLORHAM PARK, NJ 07932, UNITED STATES

Auditor

Deloitte & Touche LLP

Share holders

106

Employees

120

Celularity Inc - Class A Statistics

Valuation Measures

Market Capitalization²

43.31M

Enterprise Value

85.79M

Enterprise Value/EBITDA(ttm)

-11.56

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.01

Price to Book(mrq)

1.75

Price to Cash(ytd)

0.30

Profitability

Gross Margin(ttm)

49.21%

Operating Margin(ttm)

-72.72%

Profit Margin(ttm)

-651.06%

Return on Equity(ttm)

-119.53%

Return on Invested Capital(ttm)

-380.84%

Return on Assets(ttm)

-25.40%

Income Statement

Revenue(ttm)

48.20M

Revenue Per Share(ttm)

2.14

Gross Profit(ttm)

30.95M

EBITDA(ttm)³

-7.42M

Net Income Available to Common(ttm)

-35.05M

Diluted EPS(ttm)

Share Statistics

Beta (5Y Monthly)

0.64

52-Week Change

5.96%

S&P 500 52-Week Change

25.68%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

22.48M

Dividend Yield

0.00%

Float⁴

17.13M

% Held by Insiders

22.10%

% Held by Institutions

19.02%

Balance Sheet

Total Cash(mrq)

133.00K

Total Cash Per Share(mrq)

0.01

Total Debt(mrq)

42.61M

Total Debt/Equity(mrq)

147.42%

Current Ratio(mrq)

0.26%

Quick Ratio(mrq)

0.22%

Book Value Per Share(mrq)

1.27

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.36

Free Cash Flow(ytd)

-7.92M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CELU

Celularity Inc - Class A

Celularity Inc - Class A Profile